1. Home
  2. GSIW vs GBIO Comparison

GSIW vs GBIO Comparison

Compare GSIW & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSIW
  • GBIO
  • Stock Information
  • Founded
  • GSIW 2016
  • GBIO 2016
  • Country
  • GSIW Hong Kong
  • GBIO United States
  • Employees
  • GSIW N/A
  • GBIO N/A
  • Industry
  • GSIW
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSIW
  • GBIO Health Care
  • Exchange
  • GSIW Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • GSIW 27.2M
  • GBIO 29.2M
  • IPO Year
  • GSIW 2023
  • GBIO 2020
  • Fundamental
  • Price
  • GSIW $1.63
  • GBIO $0.56
  • Analyst Decision
  • GSIW
  • GBIO Strong Buy
  • Analyst Count
  • GSIW 0
  • GBIO 4
  • Target Price
  • GSIW N/A
  • GBIO $7.33
  • AVG Volume (30 Days)
  • GSIW 2.6M
  • GBIO 1.7M
  • Earning Date
  • GSIW 01-01-0001
  • GBIO 08-06-2025
  • Dividend Yield
  • GSIW N/A
  • GBIO N/A
  • EPS Growth
  • GSIW N/A
  • GBIO N/A
  • EPS
  • GSIW N/A
  • GBIO N/A
  • Revenue
  • GSIW $1,313,795.00
  • GBIO $24,556,000.00
  • Revenue This Year
  • GSIW N/A
  • GBIO N/A
  • Revenue Next Year
  • GSIW N/A
  • GBIO N/A
  • P/E Ratio
  • GSIW N/A
  • GBIO N/A
  • Revenue Growth
  • GSIW N/A
  • GBIO 146.47
  • 52 Week Low
  • GSIW $0.35
  • GBIO $0.30
  • 52 Week High
  • GSIW $12.30
  • GBIO $3.65
  • Technical
  • Relative Strength Index (RSI)
  • GSIW 72.13
  • GBIO 67.17
  • Support Level
  • GSIW $1.26
  • GBIO $0.32
  • Resistance Level
  • GSIW $1.66
  • GBIO $0.36
  • Average True Range (ATR)
  • GSIW 0.14
  • GBIO 0.03
  • MACD
  • GSIW -0.02
  • GBIO 0.02
  • Stochastic Oscillator
  • GSIW 92.25
  • GBIO 94.21

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: